These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9475828)

  • 1. Low-molecular-weight heparins for acute coronary syndromes.
    Spinler SA; Nawarskas JJ
    Ann Pharmacother; 1998 Jan; 32(1):103-10. PubMed ID: 9475828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
    Magee KD; Sevcik W; Moher D; Rowe BH
    Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
    Turpie AG
    Can J Cardiol; 1998 Aug; 14 Suppl E():20E-23E. PubMed ID: 9779029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
    Kaul S; Shah PK
    J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparins in the management of unstable angina.
    Agnelli G; Sonaglia F
    Haemostasis; 2000; 30 Suppl 2():158-67; discussion 146-7. PubMed ID: 11251362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparins in the treatment of deep-vein thrombosis.
    Martineau P; Tawil N
    Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparins and coronary artery disease.
    Zed PJ
    Curr Cardiol Rep; 2000 Jan; 2(1):61-8. PubMed ID: 10980874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    De Luca G; Marino P
    Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.
    Wong GC; Giugliano RP; Antman EM
    JAMA; 2003 Jan; 289(3):331-42. PubMed ID: 12525234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparins for the treatment of acute coronary syndromes.
    Wong GC; Giugliano RP
    Semin Vasc Med; 2003 Nov; 3(4):391-402. PubMed ID: 15199446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular weight heparins in venous and arterial thrombotic disease.
    Bijsterveld NR; Hettiarachchi R; Peters R; Prins MH; Levi M; Büller HR
    Thromb Haemost; 1999 Sep; 82 Suppl 1():139-47. PubMed ID: 10695506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparin in acute coronary syndromes.
    Cannon CP
    Curr Cardiol Rep; 1999 Sep; 1(3):206-11. PubMed ID: 10980843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
    Nicolau JC; Cohen M; Montalescot G
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparins and unstable angina--current perspectives.
    Turpie AG
    Haemostasis; 1997; 27 Suppl 1():19-24. PubMed ID: 9439754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of low-molecular-weight heparins in cardiovascular medicine.
    Hödl R; Klein W
    J Clin Pharm Ther; 2003 Oct; 28(5):371-8. PubMed ID: 14632961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic equivalency of low-molecular-weight heparins.
    McCart GM; Kayser SR
    Ann Pharmacother; 2002 Jun; 36(6):1042-57. PubMed ID: 12022908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
    Dolovich LR; Ginsberg JS; Douketis JD; Holbrook AM; Cheah G
    Arch Intern Med; 2000 Jan; 160(2):181-8. PubMed ID: 10647756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of the low-molecular-weight heparins.
    Turpie AG
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S329-35. PubMed ID: 9628446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.